Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CASI Pharmaceuticals stock | $2.78

Own CASI Pharmaceuticals stock in just a few minutes.

Fact checked

CASI Pharmaceuticals, Inc is a biotechnology business based in the US. CASI Pharmaceuticals shares (CASI) are listed on the NASDAQ and all prices are listed in US Dollars. CASI Pharmaceuticals employs 125 staff and has a trailing 12-month revenue of around USD$11.7 million.

How to buy shares in CASI Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CASI Pharmaceuticals. Find the stock by name or ticker symbol: CASI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CASI Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.78, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of CASI Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CASI Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

CASI Pharmaceuticals share price

Use our graph to track the performance of CASI stocks over time.

CASI Pharmaceuticals shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$2.78
52-week rangeUSD$1.3401 - USD$3.32
50-day moving average USD$2.3948
200-day moving average USD$2.0559
Wall St. target priceUSD$4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.444

Buy CASI Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CASI Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CASI Pharmaceuticals price performance over time

Historical closes compared with the close of $2.78 from 2020-12-18

1 week (2021-01-11) -6.71%
1 month (2020-12-18) 2.78
3 months (2020-10-16) 68.48%
6 months (2020-07-17) 22.47%
1 year (2020-01-17) -13.13%
2 years (2019-01-18) -23.63%
3 years (2018-01-18) 3.98
5 years (2016-01-15) 286.11%

CASI Pharmaceuticals financials

Revenue TTM USD$11.7 million
Gross profit TTM USD$196,000
Return on assets TTM -17.67%
Return on equity TTM -42.85%
Profit margin 0%
Book value $0.738
Market capitalisation USD$363.2 million

TTM: trailing 12 months

Shorting CASI Pharmaceuticals shares

There are currently 1.9 million CASI Pharmaceuticals shares held short by investors – that's known as CASI Pharmaceuticals's "short interest". This figure is 1.5% up from 1.9 million last month.

There are a few different ways that this level of interest in shorting CASI Pharmaceuticals shares can be evaluated.

CASI Pharmaceuticals's "short interest ratio" (SIR)

CASI Pharmaceuticals's "short interest ratio" (SIR) is the quantity of CASI Pharmaceuticals shares currently shorted divided by the average quantity of CASI Pharmaceuticals shares traded daily (recently around 411580.39215686). CASI Pharmaceuticals's SIR currently stands at 4.59. In other words for every 100,000 CASI Pharmaceuticals shares traded daily on the market, roughly 4590 shares are currently held short.

However CASI Pharmaceuticals's short interest can also be evaluated against the total number of CASI Pharmaceuticals shares, or, against the total number of tradable CASI Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CASI Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 CASI Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0219% of the tradable shares (for every 100,000 tradable CASI Pharmaceuticals shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CASI Pharmaceuticals.

Find out more about how you can short CASI Pharmaceuticals stock.

CASI Pharmaceuticals share dividends

We're not expecting CASI Pharmaceuticals to pay a dividend over the next 12 months.

Have CASI Pharmaceuticals's shares ever split?

CASI Pharmaceuticals's shares were split on a 1:11 basis on 1 July 2010. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CASI Pharmaceuticals shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for CASI Pharmaceuticals shares which in turn could have impacted CASI Pharmaceuticals's share price.

CASI Pharmaceuticals share price volatility

Over the last 12 months, CASI Pharmaceuticals's shares have ranged in value from as little as $1.3401 up to $3.32. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CASI Pharmaceuticals's is 0.4205. This would suggest that CASI Pharmaceuticals's shares are less volatile than average (for this exchange).

CASI Pharmaceuticals overview

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site